دورية أكاديمية
Novel insights into molecular and immune subtypes of biliary tract cancers.
| العنوان: | Novel insights into molecular and immune subtypes of biliary tract cancers. |
|---|---|
| المؤلفون: | Bramel ER; Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Sia D; Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: daniela.sia@mssm.edu. |
| المصدر: | Advances in cancer research [Adv Cancer Res] 2022; Vol. 156, pp. 167-199. Date of Electronic Publication: 2022 Feb 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0370416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-5557 (Electronic) Linking ISSN: 0065230X NLM ISO Abbreviation: Adv Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2008>- : Amsterdam : Elsevier Original Publication: New York : Academic Press |
| مواضيع طبية MeSH: | Bile Duct Neoplasms*/pathology , Biliary Tract Neoplasms*/drug therapy , Biliary Tract Neoplasms*/genetics , Biliary Tract Neoplasms*/pathology , Cholangiocarcinoma*/genetics , Cholangiocarcinoma*/pathology, Bile Ducts, Intrahepatic/pathology ; Humans ; Prognosis ; Tumor Microenvironment |
| مستخلص: | Biliary tract cancers (BTCs), which include cholangiocarcinoma (CCA) and gallbladder cancer (GBC), are heterogenous malignancies characterized by distinct molecular features often associated with specific clinical traits and/or outcomes. Such complex molecular heterogeneity, both within each BTC subtype and between distinct subtypes, poses a great challenge to personalized medicine. Recent technological advances have allowed the integration of multiple -omics derived from large cohorts of patients with distinct solid cancers to ultimately design stratification algorithms for prognostic prediction or more efficient treatment allocation. In this regard, although BTCs lag behind other tumors when it comes to our understanding of their molecular complexity, over the past decade, tremendous efforts have been made to generate supervised or unsupervised molecular classifications. As a result, CCAs and GBCs can be assigned to distinct molecular and/or prognostic classes. Notably, the discovery of biologically relevant subgroups of tumors harboring frequent targetable alterations (i.e., mutations in IDH1, FGFR2 fusion proteins) holds important therapeutic implications for BTCs, particularly iCCA. Furthermore, the recent application of single cell-based technologies or more conservative (and less precise) "virtual microdissection" algorithms to isolate signals derived from the immune and stromal cells has identified the first microenvironment-based classes. In this chapter, we will review the molecular and immune classes of BTCs, with a particular focus on their clinical implications. Competing Interests: Conflict of interest statement E. B. and D. S. have no financial or personal disclosures relevant to the contents of this manuscript. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cholangiocarcinoma; Expression profiling; Gallbladder cancer; Genomic landscape; Integrative omics; Molecular classes; Next-generation sequencing; Precision medicine; Virtual microdissection |
| تواريخ الأحداث: | Date Created: 20220812 Date Completed: 20220816 Latest Revision: 20221209 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/bs.acr.2022.01.008 |
| PMID: | 35961699 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2162-5557 |
|---|---|
| DOI: | 10.1016/bs.acr.2022.01.008 |